Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study.
Bauckneht M, Rebuzzi SE, Signori A, Donegani MI, Murianni V, Miceli A, Borea R, Raffa S, Damassi A, Ponzano M, Catalano F, Martelli V, Marini C, Boccardo F, Morbelli S, Sambuceti G, Fornarini G. Bauckneht M, et al. Among authors: murianni v. Cancers (Basel). 2020 Oct 31;12(11):3213. doi: 10.3390/cancers12113213. Cancers (Basel). 2020. PMID: 33142739 Free PMC article.
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, Prelaj A, Coco S, Longo L, Dal Bello MG, Alama A, Dellepiane C, Bennicelli E, Malapelle U, Genova C. Rebuzzi SE, et al. Among authors: murianni v. Int J Mol Sci. 2021 Mar 5;22(5):2625. doi: 10.3390/ijms22052625. Int J Mol Sci. 2021. PMID: 33807876 Free PMC article. Review.
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.
Rebuzzi SE, Cerbone L, Signori A, Santoni M, Murianni V, De Giorgi U, Procopio G, Porta C, Milella M, Basso U, Massari F, Maruzzo M, Iacovelli R, Battelli N, Carmisciano L, Banna GL, Buti S, Fornarini G. Rebuzzi SE, et al. Among authors: murianni v. Ther Adv Med Oncol. 2022 Feb 26;14:17588359221079580. doi: 10.1177/17588359221079580. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35237353 Free PMC article.
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M, Rebuzzi SE, Signori A, Frantellizzi V, Murianni V, Lodi Rizzini E, Mascia M, Lavelli V, Donegani MI, Ponzano M, Gaudiano A, Stazza ML, Licari M, Cavallini L, Laghi V, Cindolo L, Maggi M, Sciarra A, Mammucci P, Sambuceti G, Costa RP, Spanu A, Rubini G, Monari F, De Vincentis G, Fornarini G. Bauckneht M, et al. Among authors: murianni v. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1063-1074. doi: 10.1007/s00259-021-05550-6. Epub 2021 Sep 6. Eur J Nucl Med Mol Imaging. 2022. PMID: 34486070 Free PMC article.
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network.
Rescigno P, Maruzzo M, Rebuzzi SE, Murianni V, Cinausero M, Lipari H, Fratino L, Gamba T, De Giorgi U, Caffo O, Bimbatti D, Dri A, Mosca A, Giunta EF, Ermacora P, Vignani F, Msaki A, Bonifacio B, Lombardo V, Conteduca V, Basso U, Fornarini G, Banna GL. Rescigno P, et al. Among authors: murianni v. Oncologist. 2022 Dec 9;27(12):e949-e956. doi: 10.1093/oncolo/oyac147. Oncologist. 2022. PMID: 35920559 Free PMC article.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Catalano F, Brunelli M, Signori A, Rescigno P, Buti S, Galli L, Spada M, Masini C, Galuppini F, Vellone VG, Gaggero G, Maruzzo M, Merler S, Vignani F, Cavo A, Bimbatti D, Milella M, Dei Tos AP, Sbaraglia M, Murianni V, Damassi A, Cremante M, Maffezzoli M, Llaja Obispo MA, Banna GL, Fornarini G, Rebuzzi SE. Catalano F, et al. Among authors: murianni v. Future Oncol. 2024 Apr 29. doi: 10.2217/fon-2023-1068. Online ahead of print. Future Oncol. 2024. PMID: 38682738
20 results